Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Stock Information

Intec Pharma Ltd. Company Name:

NTEC Stock Symbol:

NASDAQ Market:

MENU
NTEC NTEC Quote NTEC Short NTEC News NTEC Articles NTEC Message Board
Get NTEC Alerts

News, Short Squeeze, Breakout and More Instantly...

RECENT NTEC NEWS
  • NTEC - Intec Pharma to Present at LD Micro's 12th Annual Main Event

    JERUSALEM , Dec. 6, 2019 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12 th Annual LD Micro Main Event investor conference. 12 th  Annual LD Micro Main Event Dat...

  • NTEC - Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

    JERUSALEM , Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicag...

  • NTEC - Intec Pharma to Participate in Jefferies London Healthcare Conference

    JERUSALEM , Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference.  Jefferies London Healthcare Conference Date: November 20-21, 2019 ...

Intec Pharma to Participate in Jefferies London Healthcare Conference


home / news releases / Intec Pharma to Participate in Jefferies London Healthcare Conference

  • November, 13 2019 07:00 AM
  • |
  • PR Newswire
  • |
    • NTEC
    • NTEC Quote
    • NTEC Short
    • NTEC News
    • NTEC Articles
    • NTEC Message Board

JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. 

Jefferies London Healthcare Conference
Date: November 20-21, 2019
Company Presentation: Wednesday, November 20, 2019 at 7:20 am (GMT)
Location:  The Waldorf Hilton Hotel, London
Presenter:  Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma
Format: Corporate presentation and One-on-One Investor Meetings

Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage development for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications. In addition, the Company has a feasibility agreement for the development of a custom-designed Accordion Pill for a proprietary compound with Novartis Pharmaceuticals and a research collaboration with Merck & Co. 

For more information, visit www.intecpharma.com. Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: our limited operating history and history of operating losses, our ability to continue as a going concern, our ability to obtain additional financing, our ability to successfully operate our business or execute our business plan, our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us, the timing and cost of our clinical trials, the completion and receiving favorable results in our clinical trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to protect and maintain our intellectual property and licensing arrangements, our ability to develop, manufacture and commercialize our product candidates, the risk of product liability claims, the availability of reimbursement, and the influence of extensive and costly government regulation and our ability to remain listed on the Nasdaq Capital Market. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in our most recent Annual Report on Form 10-K filed with the SEC on February 27, 2019, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Intec Pharma Investor Contact:
Anne Marie Fields                             
VP-Corporate Communications & Investor Relations
646-200-8808                                     
amf@intec-us.com                

 

 

SOURCE Intec Pharma Ltd.

Tags
  • Pharmaceutical
  • Europe
  • Healthcare
  • Health Services
  • Hospitals
  • Medical Marijuana
Share This Post

Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.

Contact the Author

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Member Benefits
  • Member Coins
  • Sign Up
  • Login
  • Contact

Sign up or login to continue

Sign up or login to continue.




Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Member Benefits

Member Coins


Log In

Sign Up

Stay Connected
Follow @marketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2018 Market Wire News